Xilio Therapeutics Executives Sell Shares in Late January 2026

lunes, 5 de enero de 2026, 4:53 pm ET1 min de lectura
XLO--

Xilio Therapeutics, Inc. (XLO) has announced that Brennan Kevin M., Senior Vice President of Finance and Accounting, has sold 1,826 shares at $0.64 per share on January 2, 2026. Furthermore, Christopher James Frankenfield, Chief Financial Officer, has sold 7,030 shares at $0.64 per share on the same date.

Xilio Therapeutics Executives Sell Shares in Late January 2026

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios